Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3133453
Max Phase: Preclinical
Molecular Formula: C70H89N19O17S4
Molecular Weight: 1596.87
Molecule Type: Protein
Associated Items:
ID: ALA3133453
Max Phase: Preclinical
Molecular Formula: C70H89N19O17S4
Molecular Weight: 1596.87
Molecule Type: Protein
Associated Items:
Canonical SMILES: CC(C)[C@@H]1NC(=O)[C@@H](N)CSSC[C@@H](C(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](C)NC1=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N2
Standard InChI: InChI=1S/C70H89N19O17S4/c1-34(2)56-69(105)78-35(3)59(95)80-47(21-38-14-16-42(91)17-15-38)63(99)86-53-30-109-110-31-54(68(104)82-49(22-39-25-75-45-13-9-8-12-43(39)45)66(102)89-57(36(4)90)70(106)85-52(58(72)94)29-108-107-28-44(71)60(96)88-56)87-65(101)51(24-41-27-74-33-77-41)84-64(100)50(23-40-26-73-32-76-40)83-61(97)46(18-19-55(92)93)79-62(98)48(81-67(53)103)20-37-10-6-5-7-11-37/h5-17,25-27,32-36,44,46-54,56-57,75,90-91H,18-24,28-31,71H2,1-4H3,(H2,72,94)(H,73,76)(H,74,77)(H,78,105)(H,79,98)(H,80,95)(H,81,103)(H,82,104)(H,83,97)(H,84,100)(H,85,106)(H,86,99)(H,87,101)(H,88,96)(H,89,102)(H,92,93)/t35-,36+,44-,46-,47-,48-,49-,50-,51-,52-,53-,54-,56-,57-/m0/s1
Standard InChI Key: DASOYSLLDJHBMP-GVGXEWTNSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1596.87 | Molecular Weight (Monoisotopic): 1595.5567 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Meinander K, Weisell J, Pakkala M, Tadd AC, Hekim C, Kallionpaa R, Widell K, Stenman U, Koistinen H, Narvanen A, Vepsalainen J, Luthman K, Wallen EAA. (2013) Pseudopeptides with a centrally positioned alkene-based disulphide bridge mimetic stimulate kallikrein-related peptidase 3 activity, 4 (3): [10.1039/C3MD20292E] |
Source(1):